Literature DB >> 462569

Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.

C Greco, A Corsi, M Caputo, A Cavallari, F Calabresi.   

Abstract

In the present report, investigations have been carried out to evaluate toxic and therapeutic effects of cyclophosphamide vs its isomer iphosphamide. Cytostatic action of the 2 drugs was assayed on the murine Lewis lung carcinoma (3LL). It has been observed that iphosphamide is less toxic as compared to cyclophosphamide (LD50 IP LD50 CP = 1.5); on the other hand, to reach the same therapeutic effectiveness on 3LL, an iphosphamide dose 1.6 - 2 times higher than that of its parent compound is necessary.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 462569     DOI： 10.1177/030089167906500205

Source DB:  PubMed          Journal:  Tumori        ISSN： 0300-8916


  4 in total

1.  N-methylformamide affects spontaneous metastases of 3LL lines and increases natural killer activity of tumor-bearing mice.

Authors:  C Greco; D Del Bufalo; D Giannarelli; M Marangolo; M P Fuggetta; E Bonmassar; G Zupi
Journal:  Clin Exp Metastasis       Date:  1990 Mar-Apr       Impact factor: 5.150

2.  Influence of scheduling on therapeutic and toxic effect of AMSA in Lewis lung carcinoma.

Authors:  C Greco; G Zupi; G Badaracco
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 3.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).

Authors:  L Tentori; C Leonetti; F Lozupone; E Bonmassar
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.